ESX1

Across TCGA pan-cancer cohorts, ESX1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ESX1 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ESX1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ESX1 expression acts as an unfavorable survival marker.

HNSC, COAD, and LIHC are the cancer types where ESX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.156	0.673	.024	12	view →
COAD	OS	Median	All	0.117	0.809	<.001	12	view →
LIHC	OS	Median	All	0.507	0.777	<.001	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCS	OS	Median	All	0.236	0.590	.042	6	view →
BLCA	OS	Median	III,IV	0.228	0.684	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ESX1–HNSC (OS)

Open the HNSC breakdown →